About Immunohistochemistry

The mandate of the Immunohistochemistry and Molecular Pathology Core is to facilitate immunohistochemical and molecular genetic analyses of tumor materials by:

  • Development of immunohistochemistry (IHC) and immunofluorescence (IMF) assays, and in collaboration with Center members.
  • Performance of routine IHC analyses of animal and human tissue sections and cell lines.
  • Performance of IHC and IMF analysis of tissue arrays produced by the HDFCCC Tissue Core.
  • In situ hybridization on thin sections to analyze gene expression via detection of specific mRNAs, using ACD RNA scope technology.



Routine Immunohistochemistry Staining
Standard protocols have been developed for a number of antibodies (see list). Sections of paraffin-embedded tissue to be stained should be brought to the Core laboratory, 2340 Sutter Street, Room S-241, between 8:00 am and 4:30 pm Monday-Friday. The tissue must be accompanied by a completed work order form. If tissue sections are not available, the paraffin block may be brought to the Core laboratory for sectioning. Services are ordered online through the MyCORES website. .

Protocol Development for Novel Antibodies
The laboratory assists in the development of protocols for novel antibodies. Investigators should meet with Core Manager Hubert Stoppler PhD (415-476-0435) and/or Director Scott VandenBerg MD, PhD, (415-514-4978) to discuss this service. The investigator should be prepared to provide the antibody, references of its use in immunohistochemistry, positive and negative controls, information from Western analyses, and sections of the tissues to be stained.


For a fee, training in IHC techniques is informal and hands-on, and takes place as time permits. Contact 415-476-0435 to schedule a session. Core personnel are also available to train researchers in molecular cytogenetic techniques, comprising both didactic sessions and hands-on laboratory experience.

Additional Resources
A searchable database of core facilities at all UCSF campus locations, provided by the Clinical and Translational Science Institute at UCSF, is available here.

This unit is supported by a National Cancer Institute Cancer Center Support Grant (5P30CA082103). Any publications related to work done by this core should reference grant number 5P30CA082103 and must include a PMCID as required by the NIH. For complete instructions on how to acknowledge funding sources, please see http://grants.nih.gov/grants/acknow.htm. For more information on how to obtain a PMCID, please see http://publicaccess.nih.gov/submit_process.htm.

For more information on the CCSG, please contact Kate Shumate at kate.shumate@ucsf.edu.